Scientific Program
| Thursday, October 27 | |
| 17:30–18:00 | Industry-supported Meet the Expert Session |
| 18:30 | Welcome Reception |
| Friday, October 28 | ||
| HALL A | ||
| 09:00–10:30 | Session 1: Opening Session-CAR vs. HSCT | |
| 09:00–09:10 | Welcome note: Nicolaus Kröger, Germany; Arnon Nagler, Israel | |
| 09:10–09:40 | Controversy: Does CAR T cell replace stem cell transplantation in DLBCL? Chair: Nicolaus Kröger, Germany |
|
| 09:10–09:25 | Yes: Anna Sureda, Spain | |
| 09:25–09:40 | No: Michael Bishop, USA | |
| 09:40–10:00 | Controversy: Will CAR-T-cell replace stem cell transplantation in MM? Chair: Arnon Nagler, Israel |
|
| 09:40–09:55 | Yes: Noopur Raje, USA | |
| 09:55–10:10 | No: Philippe Moreau, France | |
| 10:10–10:30 | Panel discussion: All | |
| 10:30–11:00 | Coffee Break, Poster Viewing and Visit Exhibition | |
| HALL A | HALL B | |
| 11:00–12:30 | Session 2: AML | Session 3: Infection complications |
| 11:00–11:30 | Controversy: Should MRD positivity targeted prior SCT or after SCT? Chair: Yi-Bin Chen, USA |
Controversy: Letermovir prophylaxis as secondary prophylaxis? Chair: Rafael de la Cámara, Spain |
| 11:00–11:15 | Prior: Arnon Nagler, Israel | Yes: Michael Boeckh, USA |
| 11:15–11:30 | After: Michael Heuser, Germany | No: Per Ljungman, Sweden |
| 11:30–12:00 | Controversy: Narrow vs. broad (specific vs. nonspecific) TKI post Allo in FLT3+AML Chair: Andreas Burchert, Germany |
Controversy: Are there evidence-based arguments for a general compulsory SarsCoV2 vaccinations? Chair: Per Ljungman, Sweden |
| 11:30–11:45 | Broad: Xiaojun Huang, China | Yes: Simone Cesaro, Italy |
| 11:45–12:00 | Narrow: Yi-Bin Chen, USA | No: TBA |
| 12:00–12:30 | Panel discussion: All | Panel discussion: All |
| 12:30–13:00 | Lunch Pick-up, Poster Viewing and Visit Exhibition | |
| 13:00–14:00 | Industry-supported Symposium |
|
| 14:00–14:15 | Short Break | |
| HALL A | HALL B | |
| 14:15–15:45 | Session 4: GVHD prophylaxis /Treatment (1) | Session 5: MDS |
| 14:15–14:45 | Controversy: Is there still a role for T cell depletion (CD34 purification) as GVHD prophylaxis in HLA matched (MSD and MUD) Allograft? Chair: Leonido Luznik, USA |
Controversy: Are sequential conditioning regimens the standard for MDS EB1 and EB2? Chair: Bart Lee Scott, USA |
| 14:15–14:30 | Yes: Miguel Perales, USA | Yes: Thomas Schroeder, Germany |
| 14:30–14:45 | No: Marcelo Pasquini, USA | No: Avichai Shimoni, Israel |
| 14:45–15:15 | Controversy: Can we modify schedule or dosing of PTCy? Chair: Marcelo Pasquini, USA |
Controversy: Is the new Molecular IPSS helpful for decision making regarding allo? Chair: Avichai Shimoni, Israel |
| 14:45–15:00 | Yes: Christopher Kanakry, USA | Yes: Matteo Della Porta, Italy |
| 15:00–15:15 | No: Leonido Luznik, USA | No: Bart Lee Scott, USA |
| 15:15–15:45 | Panel discussion: All | Panel discussion: All |
| 15:45–16:15 | Coffee Break, Poster Viewing and Visit Exhibition | |
| 16:15–17:15 | Industry-supported Symposium | |
| 17:15–17:30 | Short Break | |
| HALL A | HALL B | |
| 17:30–19:00 | Session 6: GVHD prophylaxis/ Treatment (2) | Session 7: ALL |
| 17:30–18:00 | Controversy: Do novel agents replace ECP as second line treatment in cGvHD? Chair: Steven Pavletic, USA |
Controversy: Is lower than 12 Gy TBI dose justified as conditioning for allo in young adult ALL? Chair: Sebastian Giebel, Poland |
| 17:30–17:45 | Yes: Daniel Wolff, Germany | Yes: Alexandros Spyridonidis, Greece |
| 17:45–18:00 | No: Hildegard Greinix, Austria | No: David Marks, UK |
| 18:00–18:30 | Controversy: Is CNI plus antimetabolite still the standard GvHD prophylaxis for MUD in 2022? Chair: Hildegard Greinix, Austria |
Controversy: Is there still a place for upfront allo in Ph+ ALL? Chair: David Marks, UK |
| 18:00–18:15 | Yes: Robert Zeiser, Germany | Yes: Matthias Stelljes, Germany |
| 18:15–18:30 | No: Corey Cutler, USA | No: Robin Foà, Italy |
| 18:30–19:00 | Panel discussion: All | Panel discussion: All |
| Saturday, October 29 | ||
| HALL A | HALL B | |
| 08:00–09:30 | Session 8: Acute Leukemia and CARs | Session 9: SAA and VOD |
| 08:00–08:30 | Controversy: Can CAR T cell therapy replace allo SCT in adult ALL? Chair: Arnon Nagler, Israel |
Controversy: Can allogeneic SCT with 10/10 MUD be used as first line therapy for sAA? Chair: Carlo Dufour, Italy |
| 08:00–08:15 | Yes: Claire Roddie, UK | Yes: Andrea Bacigalupo, Italy |
| 08:15–08:30 | No: Sebastian Giebel, Poland | No: Antonio Risitano, Italy |
| 08:30–09:00 | Controversy: Is there a role of CAR T cell or therapy in AML in 2022? Chair: Marion Subklewe, Germany |
Controversy: Is there any advantage in using the EBMT adult severity grading criteria prior to a diagnosis of VOD? Chair: TBA |
| 08:30–08:45 | Yes: Saar Gill, USA | Yes: Antonio Pagliuca, UK |
| 08:45–09:00 | No: Charles Craddock, UK | No: Francesca Bonifazi, Italy |
| 09:00–09:30 | Panel discussion: All | Panel discussion: All |
| 09:30–10:00 | Coffee Break, Poster Viewing and Visit Exhibition | |
| 10:00–11:00 | Industry-supported Symposium | |
| 11:00–11:15 | Short Break | |
| HALL A | HALL B | |
| 11:15–12:45 | Session 10: Multiple Myeloma | Session 11: Lymphoma/ Lymphatic malignancies |
| 11:15–11:45 | Controversy: CAR vs. Bites in R/R MM Chair: Sergio Giralt, USA |
Controversy: NHL-patients achieving <PR 6 mo post CAR should we go Allo? Chair: David Porter, USA |
| 11:15–11:30 | CAR: Ibrahim Yakoub-Agha, France | Yes: Peggy Lu, China |
| 11:30–11:45 | BITEs: Hermann Einsele, Germany | No: TBA |
| 11:45–12:15 | Controversy: Is it still justified to collect CD34 cells for 2 or more transplants in MM? Chair: Hartmut Goldschmidt, Germany |
Controversy: Is there a role for cellular therapies in CAR-T .. CLL? Chair: TBA |
| 11:45–12:00 | Yes: Pieter Sonneveld, Netherlands | Yes: David Porter, USA |
| 12:00–12:15 | No: Sergio Giralt, USA | No: TBA |
| 12:15–12:45 | Panel discussion: All | Panel discussion: All |
| 12:45–13:15 | Lunch Pick-up, Poster Viewing and Visit Exhibition | |
| 13:15–14:15 | Industry-supported Symposium | |
| 14:15–14:30 | Short Break | |
| HALL A | HALL B | |
| 14:30–16:00 | Session 12: Myelofibrosis | Session 13: Pediatric ALL |
| 14:30–15:00 | Controversy: Does mutation panel dictate Allo indication in myelofibrosis? Chair: Alessandro Rambaldi, Italy |
Controversy: For pediatric ALL relapsing post CD19 CAR should we go to an alternative CAR? Chair: Christina Peters, Austria |
| 14:30–14:45 | Yes: Francesco Passamonti, Italy | Yes: Alan Wayne, USA |
| 14:45–15:00 | No: Nicolaus Kröger, Germany | No: Peter Bader, Germany |
| 15:00–15:30 | Controversy: Is there a role for haplo or cord blood transplantation in in myelofibrosis? Chair: Nicolaus Kröger, Germany |
Controversy: Can PBSC be used as stem cell source in MUD pediatric ALL? Chair: Alan Wayne, USA |
| 15:00–15:15 | Yes: Alessandro Rambaldi, Italy | Yes: Christina Peters, Austria |
| 15:15–15:30 | No: Nico Gagelmann, Germany | No: Michael Pulsipher, USA |
| 15:30–16:00 | Panel discussion: All | Panel discussion: All |
| 16:00–16:30 | Coffee Break, Poster Viewing and Visit Exhibition | |
| 16:30–17:30 | Industry-supported Symposium | |
| 17:30–17:45 | Short Break | |
| HALL A | HALL B | |
| 17:45–19:15 | Session 14: Stem cell donors | Session 15: Hemoglobinopathy |
| 17:45–18:15 | Controversy: Can expanded CBT compete with Haplo SCT? Chair: Vanderson Rocha, Brazil |
Controversy: Is PTCY the preferred GvHD prophylaxis after haplo-ident SCT in sickle cell anemia? Chair: Rupert Handgretinger, Germany |
| 18:15–18:30 | Yes: Guillermo Sanz, Spain | Yes: Josu de la Fuente, UK |
| 18:30–18:45 | No: Francesca Bonifazi, Italy | No: Selim Corbacioglu, Germany |
| 18:45–19:15 | Controversy: Is PBSC as stem cell source equal to BM after Haplo PTCy? Chair: Francesca Bonifazi, Italy |
Controversy: Can gene therapy replace allogeneic SCT in thalassemia? Chair: Selim Corbacioglu, Germany |
| 18:45–19:00 | Yes: Vanderson Rocha, Brazil | Yes: Rupert Handgretinger, Germany |
| 19:00–19:15 | No: TBA | No: Suradej Hongeng, Thailand |
| 19:15–19:45 | Panel discussion: All | Panel discussion: All |
| 19:45–20:30 | COSTEM Poster Walk and Awards | |
| Sunday, October 30 | |
| HALL A | |
| 09:00–10:30 | Session 16: Cellular therapies |
| 09:00–09:30 | Controversy: Can allo NK CAR complete with auto CAR T? Chair: Harry Dolstra, Netherlands |
| 09:00–09:15 | Yes: Evelyn Ullrich, Germany |
| 09:15–09:30 | No: TBA |
| 09:30–10:00 | Controversy: Is the point of care production for CAR T cell the future? Chair: TBA |
| 09:30–09:45 | Yes: Alvaro Urbano-Ispizua, Spain |
| 09:45–10:00 | No: Harry Dolstra, Netherlands |
| 10:00–10:30 | Panel discussion: All |
| 10:30–11:00 | Coffee Break |
| 11:00–12:30 | Session 17: Selection of CAR T cells |
| 11:00–11:30 | Controversy: Should we preference a CD19 CAR construct in RR DLBCL? Chair: TBA |
| 11:00–11:15 | Yes: Wolfgang Bethge, Germany |
| 11:15–11:30 | No: Marion Subklewe, Germany |
| 11:30–12:00 | Controversy: Should we preference a BMCA CAR construct in R/R myeloma? Chair: Hermann Einsele, Germany |
| 11:30–11:45 | Yes: Michael Hudecek, Germany |
| 11:45–12:00 | No: He Huang, China |
| 12:00–12:30 | Panel discussion: All |
| 12:30 | Closing remarks: Nicolaus Kröger, Germany; Arnon Nagler, Israel |